KR101022067B1 - 고순도 타크로리무스의 회수방법 - Google Patents
고순도 타크로리무스의 회수방법 Download PDFInfo
- Publication number
- KR101022067B1 KR101022067B1 KR1020080050779A KR20080050779A KR101022067B1 KR 101022067 B1 KR101022067 B1 KR 101022067B1 KR 1020080050779 A KR1020080050779 A KR 1020080050779A KR 20080050779 A KR20080050779 A KR 20080050779A KR 101022067 B1 KR101022067 B1 KR 101022067B1
- Authority
- KR
- South Korea
- Prior art keywords
- tacrolimus
- polar solvent
- extracting
- concentrating
- primary
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
배지 |
부피 (L) |
순도 (%) | 역가 (g/L) |
|||||||
Imp.1. | Imp.2. | Imp.3. | T2 | T1 | FK520 | FK506 | T-B | |||
실시예 1-1 | 2,500 | 99.1 | 0.04 | 0.01 | 0.04 | 0.04 | 0.10 | 0.66 | 0.02 | 0.15 |
실시예 1-2 | 2,500 | 99.1 | 0.03 | 0.01 | 0.06 | 0.03 | 0.05 | 0.71 | 0.02 | 0.20 |
배지 |
순도 (%) | 타크로리무스 (g) HPLC caled. |
|||||||
Imp.1. | Imp.2. |
Imp.3. | T2 | T1 | FK520 | FK506 | T-B | ||
실시예 2-1 | 99.1 | 0.03 | 0.01 | 0.03 | 0.03 | 0.10 | 0.70 | 0.02 | 90 |
실시예 2-2 | 99.0 | 0.03 | 0.01 | 0.04 | 0.03 | 0.05 | 0.76 | 0.02 | 100 |
배지 |
부피 (L) |
순도 (%) | 수율 (%) |
|||||||
Imp.1. | Imp.2. | Imp.3. | T2 | T1 | FK520 | FK506 | T-B | |||
실시예 3-1 | 2,500 | 20.72 | 11.30 | 1.78 | 1.87 | 0.81 | 3.21 | 55.66 | 3.65 | 81 |
실시예 3-2 | 2,500 | 12.14 | 21.00 | 1.12 | 2.01 | 2.02 | 7.30 | 47.63 | 4.78 | 76 |
실시예 3-3 | 4.47 | 0.84 | 0.88 | 0.86 | 0.24 | 3.07 | 86.17 | 3.47 | 90 |
배지 |
순도 (%) | 수율 (%) |
|||||||
Imp.1. | Imp.2. | Imp.3. | T2 | T1 | FK520 | FK506 | T-B | ||
실시예 4-1 | 0.30 | 0.77 | 0.70 | 0.50 | 0.16 | 1.75 | 95.10 | 0.52 | 80 |
실시예 4-2 | 0.08 | 0.36 | 0.12 | 0.41 | 0.11 | 1.82 | 96.52 | 0.28 | 86 |
실시예 4-3 | 0.10 | 0.46 | 0.18 | 0.51 | 0.21 | 1.42 | 96.12 | 0.30 | 84 |
실시예 5 | 0.12 | 0.46 | 0.18 | 0.54 | 0.23 | 0.99 | 96.00 | 0.10 | 95 |
배지 |
순도 (%) | 수율 (%) |
|||||||
Imp.1. | Imp.2. | Imp.3. | T2 | T1 | FK520 | FK506 | T-B | ||
실시예 6-1 | 0.14 | 0.07 | 0.03 | 0.79 | 98.7 | 0.21 | 90 | ||
실시예 6-2 | 0.09 | 0.01 | 0.01 | 0.30 | 99.50 | 0.03 | 95 | ||
실시예 6-3 | 0.02 | 0.01 | 0.02 | 0.03 | 0.17 | 99.67 | 0.02 | 93 |
Claims (9)
- 타크로리무스를 생산하는 스트렙토마이세스 속의 균주를 배양하여 얻어진 발효 배양액을 메탄올, 아세톤 또는 에탄올로 추출 및 여과하는 공정; 여액을 1차 정제 수지인 비이온성 흡착수지에 흡착시키고 용리하여 수득하는 공정; 1차 정제 농축액을 클로로포름 또는 에틸아세테이트로 추출,농축하여 톨루엔 또는 헥산에 트리에틸아민수용액을 혼합시켜 알칼리화시킨 비극성용매로 석출하는 공정; 석출물을 용해하여 2차 정제수지인 플래시 컬럼에 흡착시키고, 은염이 포함된 수용성 용매로 용리하여 농축하는 공정; 2차 정제농축액을 비수용성 극성용매로 추출 및 농축하고, 탈색 및 은염을 제거하기 위하여 활성탄을 사용하는 공정; 및 극성용매로 결정화하는 공정으로 이루어진 타크로리무스 회수 방법.
- 삭제
- 제1항에 있어서, 발효 배양액을 메탄올, 아세톤 또는 에탄올로 추출 및 여과하는 공정은 발효배양액에 극성용매를 동일한 부피로 첨가하여 추출, 여과하여 정제하거나 또는 균사체 덩어리만 따로 분리하여 극성용매로 추출한 후, 여액과 합하여 정제하는 것을 특징으로 하는 방법.
- 삭제
- 삭제
- 제1항에 있어서, 알칼리화시킨 비극성 용매가 톨루엔 또는 헥산에 트리에틸아민수용액을 1:2의 비율로 혼합시킨 용액인 것을 특징으로 하는 방법.
- 제1항에 있어서, 1차 및 2차 정제 수지가 각각 독립적으로 SP825, HP2MG, HP20, CG161, CG300 및 SP20SS 로부터 선택되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 1차 및 2차 정제의 용리액은 각각 독립적으로 은염을 포함하거나 포함하지 않는 용매로써 아세톤, 아세토니트릴, 이소프로판올 및 메탄올로부터 선택되는 것을 특징으로 하는 방법.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080050779A KR101022067B1 (ko) | 2008-05-30 | 2008-05-30 | 고순도 타크로리무스의 회수방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080050779A KR101022067B1 (ko) | 2008-05-30 | 2008-05-30 | 고순도 타크로리무스의 회수방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090124511A KR20090124511A (ko) | 2009-12-03 |
KR101022067B1 true KR101022067B1 (ko) | 2011-03-17 |
Family
ID=41686443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080050779A KR101022067B1 (ko) | 2008-05-30 | 2008-05-30 | 고순도 타크로리무스의 회수방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101022067B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102645011B1 (ko) | 2023-10-17 | 2024-03-07 | 주식회사 라이프슈티컬 | 고상 추출법을 이용한 타크롤리무스의 정제방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030168409A1 (en) | 1999-09-08 | 2003-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Method for separating lactone-containing high-molecular weight compounds |
KR20070057910A (ko) * | 2004-09-10 | 2007-06-07 | 아이박스 파마슈티컬스 에스.알.오. | 결정질 타크롤리무스의 분리 방법 |
KR20080024286A (ko) * | 2006-09-13 | 2008-03-18 | 동국제약 주식회사 | 타크로리무스를 고수율 및 고순도로 정제하는 방법 |
-
2008
- 2008-05-30 KR KR1020080050779A patent/KR101022067B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030168409A1 (en) | 1999-09-08 | 2003-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Method for separating lactone-containing high-molecular weight compounds |
KR20070057910A (ko) * | 2004-09-10 | 2007-06-07 | 아이박스 파마슈티컬스 에스.알.오. | 결정질 타크롤리무스의 분리 방법 |
KR20080024286A (ko) * | 2006-09-13 | 2008-03-18 | 동국제약 주식회사 | 타크로리무스를 고수율 및 고순도로 정제하는 방법 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102645011B1 (ko) | 2023-10-17 | 2024-03-07 | 주식회사 라이프슈티컬 | 고상 추출법을 이용한 타크롤리무스의 정제방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20090124511A (ko) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2834033C (en) | Methods for the production of ansamitocins | |
KR101003042B1 (ko) | 고순도 타크로리무스의 정제 방법 | |
CA2499600A1 (en) | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b | |
KR20070083930A (ko) | 타크롤리무스 정제 방법 | |
CA2548297C (en) | Process for the purification of macrolides | |
US20080312447A1 (en) | Process for Isolation of Crystalline Tacrolimus | |
KR101022067B1 (ko) | 고순도 타크로리무스의 회수방법 | |
WO2005019226A1 (en) | A process for the recovery of substantially pure tricyclic macrolide | |
US20080161555A1 (en) | Purification of Tacrolimus on Supports of Vegetable Origin | |
CN111171096B (zh) | 一种多杀菌素的提取方法 | |
US20080269479A1 (en) | Process for Isolation of Macrolide Compounds | |
US5360917A (en) | Process for producing macrolide compounds | |
WO2007013017A1 (en) | A process for purification of macrolides | |
US20050261493A1 (en) | Methods for the isolation and purification of ansamitocins | |
CN112390817B (zh) | 一种盐析萃取他克莫司发酵液的方法 | |
EP2353686B1 (en) | Method for purifying fk506 by extraction with silver ion solution | |
CN1209137A (zh) | 11β-21-二羟基-2'-甲基-5'βH-孕-1,4-二烯并[17,16-D]噁唑-3,20-二酮的纯化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140402 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160307 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170214 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180222 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190306 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200212 Year of fee payment: 10 |